Polaris Group
TWSE:6550
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
43.1
76.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Polaris Group
Polaris Group
Cash from Financing Activities
Polaris Group
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Polaris Group
TWSE:6550
|
Cash from Financing Activities
NT$919.2m
|
CAGR 3-Years
797%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
SSE:688235
|
Cash from Financing Activities
¥2.6B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Tanvex BioPharma Inc
TWSE:6541
|
Cash from Financing Activities
NT$1.3B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Polaris Group
Glance View
In the competitive realm of biotechnology, Polaris Group has carved out a niche by focusing on the research and development of novel cancer therapeutics. Founded with a mission to bring innovative treatments to patients with unmet medical needs, the company has strategically positioned itself within the oncology sector. Polaris Group's approach is to harness the power of immunotherapy, aiming to develop solutions that enhance the immune system's ability to target and destroy cancer cells. This ambitious pursuit leverages cutting-edge technologies and a robust pipeline of investigational drugs, with particular emphasis on engineered drug compounds that can target specific pathways essential for cancer cell survival and proliferation. The key to Polaris Group's financial ecosystem is its revenue generation through strategic partnerships and collaborations with major pharmaceutical companies. By partnering with larger firms, Polaris is able to co-develop its breakthrough therapies, thus sharing the burden of development costs and risks. This model not only facilitates the advancement of their drug candidates but also offers potential revenue streams from milestone payments and royalties upon successful commercialization. Polaris’s business model underscores the significance of collaboration in biotech, where innovative ideas need both scientific expertise and considerable financial backing to transform into viable market solutions, ultimately contributing to the company's profitability and sustained growth in the competitive pharmaceutical landscape.
See Also
What is Polaris Group's Cash from Financing Activities?
Cash from Financing Activities
919.2m
TWD
Based on the financial report for Dec 31, 2023, Polaris Group's Cash from Financing Activities amounts to 919.2m TWD.
What is Polaris Group's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
7%
Over the last year, the Cash from Financing Activities growth was -38%. The average annual Cash from Financing Activities growth rates for Polaris Group have been 797% over the past three years , 7% over the past five years .
You don't have any saved screeners yet